Media

60° Pharmaceuticals (60P) Media center

Here you’ll find timely and relevant information about our company, including news and press.

Events

March 6-7, 2017 – Zurich, CH

60P attends the 10th Annual European Life Sciences CEO Forum (ELSCEO) as a presenter and a partnering company.

 

March 2017 – Singapore & Shanghai

60P attends AusBiotech Series.

 

June 19-22, 2017 – San Diego, CA

60P attends International Bio as a presenting and partnering company.

Press

August 9, 2018

US Food and Drug Administration Approves ARAKODA™ (tafenoquine) tablets for oral use
READ MORE

 

July 26, 2018

US FDA Advisory Committee votes in favor of Tafenoquine for the prevention of malaria
READ MORE

 

February 13, 2018 – Fort Detrick, MD

Priority Review Designation Received for Tafenoquine
READ MORE

 

February 7, 2018 – Washington DC

60P received Priority Review Designation from the USFDA for Tafenoquine (TQ) for prevention of malaria in adults
READ MORE

 

January 16, 2018

US Army Medical Research Lab Gets Fast Track Approval from FDA for Malaria Drug
READ MORE

 

January 4, 2018

60 Degrees Pharmaceuticals Fast Tracked For Malaria Drug
READ MORE

 

December 18, 2017

60P Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
READ MORE

 

May 16, 2017

60P’s investigational antimalarial agent tafenoquine is shown to be free of neurologic toxicity in adult rats according to recent study findings.
READ MORE

 

December 11, 2015

60P has received the first tranche of $4 million in a debt financing deal with Knight Therapeutics Inc. in support of our drug development program for tropical diseases.
READ MORE

 

August 31, 2015

60P has received approval to conduct a clinical study with celgosivir and modipafant in dengue patients in collaboration with Singapore General Hospital.
READ MORE

 

April 28, 2015

60P recently entered into a cooperative research and development agreement with the U.S. Army to commercialize 60P003 (Tafenoquine) for malaria prophylaxis.
READ MORE

 

July 30, 2014

60P recently entered into an exclusive licensing deal with SingHealth and Duke-National University of Singapore Graduate Medical School to further develop celgosivir (60P001) for dengue fever. 60P is preparing to conduct a Phase II clinical trial beginning in the second half of 2015.

 

June 11, 2014

One of 60P’s partners, Duke-NUS Medical School and its collaborators, completed a Phase I clinical study that demonstrated the safety of celgosivir in dengue patients and a trend toward faster NS1 clearance, suggesting the possibility of mitigating vascular permeability syndrome using glucosidase inhibitors.
READ MORE

 

April 1 2014

60P has entered into a research collaboration agreement with the Duke-NUS Medical School to investigate the utility of different combinations of dengue drugs. Dengue, like other viral diseases, will likely require a combination of different host and virus-targeted molecules to achieve useful clinical benefit. Studies performed by Dr. Subhash Vasudevan.

 

January 1, 2014

60P established a subsidiary, 60P Australia, Pty. Ltd. 60P Australia will take the lead in continuing the company’s development of dengue therapeutics.

 

April 9, 2013

Report suggests that the incidence of dengue may have been underestimated by a factor of three. Therefore, prior estimates, including our own, of economic burden and the potential market for dengue drugs, will need to be revised upward.
READ MORE

 

September 8, 2012

60P estimates the potential market for dengue drugs to be $338 million annually. Published in Antiviral Research, the study was based on publicly available information regarding medical costs and lost productivity associated with clinical cases of dengue that result in an estimated economic burden of at least $1.7 billion a year.
READ MORE

 

60P Media Relations:

Lois Kaufman

lkaufman@imsworld.com

Phone: +1 609.683.9055  x203

429,000

Deaths annually in endemic countries from malaria

125,000,000

Travelers to endemic regions per annum

390,000,000

Dengue infections per year

202-327-5422

1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036